Pharmaniaga experiences a one-time massive loss, there are several factors to consider:

The cause of the loss:

Provision of slow-moving inventories of Covid-19 vaccines of RM552.3
million. In addition, the Group has also written down the goodwill of the Indonesia manufacturing cash-generating unit of RM50.3 million

It's essential to identify the reason behind the massive loss, whether it's due to factors such as economic recession, industry-wide changes, fraud, or unexpected events. Writing off the inventories of Covid 19 vaccines is pretty expected and it is not going to happen anymore in the near future.

_________________________________________________________________________

The company's financial standing:

Can Pharmaniaga recover despite this massive loss? I don't know, but the company has current liabilities of RM 1.8 billion and a cash balance of RM 52 million, I guess some sort of cash call is expected in the near future.

________________________________________________________________________

The management's responsibility for the loss:

It is difficult to determine whether buying excessive doses of vaccines was a result of management's fault or a political move, as it could have been either an instruction or a decision. But writing down the goodwill of the Indonesia manufacturing cash-generating unit means the management bought it at a premium.

___________________________________________________________________________

The company's reputation:

Pharmaniaga mainly provides logistics and distribution services to healthcare facilities in Malaysia. The company remains resilient and its infrastructure for delivering essential medicine to rural areas continues to operate efficiently. This creates a strong competitive advantage that would

__________________________________________________________________________

Overall, a one-time massive loss and the expectation of a cash call (Rights issue) could potentially dilute shareholder equity further. Nonetheless, Pharmaniaga's efficient infrastructure in delivering essential medicines to rural areas serves as a significant competitive advantage that new entrants will find challenging to compete against.

Although there may be a possibility of government funds being injected to rescue the company, it is unlikely to follow the same path as Sapura Energy's case. The company should be able to recover to its previous state.